FDA issues GSK a warning on Tykerb letters

Share this article:

The FDA slapped GlaxoSmithKline with a warning letter for a series of Dear Healthcare Practitioner letters promoting Tykerb.

The Nov. 21 warning said the three letters – two to doctors and one to oncology nurses – “omit and minimize the most serious and important risk information for Tykerb and selectively present efficacy information.”

The GSK letters went out to healthcare practitioners in March as part of the launch campaign for the drug, indicated for the treatment of HER2+ metastatic breast cancer. Signed by Paolo Paoletti, MD, SVP, GSK Oncology Medicine Development Center, the letters advise healthcare practitioners of the drug's availability, offering efficacy and adverse events data and promoting GSK's Tykerb Cares access program.

But FDA said the letters omitted warnings and precautions from the product insert – most seriously, that on the risk of decreased left ventricular ejection fraction, as well as cautions for pregnant patients, those with severe hepatic impairment and those who have or could develop QT prolongation, while glossing over the dangers of diarrhea for Tykerb patients.

In addition, the agency said GSK overstated Tykerb's efficacy by presenting “only the more favorable of the two distinct analyses of the effect of Tykerb in breast cancer” in the letters.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.